For a self-funded employer, the pharmacy line has quietly become the part of the health plan that behaves least like insurance and most like a black box. Pharmacy now accounts for roughly a quarter of total health-plan spend, and large employers expect it to rise eleven to twelve percent in 2026 — faster than the medical trend it sits inside. The old assumption that specialty drugs drive the increase while traditional drugs stay flat has reversed: traditional drug-spend growth accelerated from about two percent in 2021 to nearly thirteen percent in 2024, driven almost entirely by GLP-1 medications. The cost is real, it is compounding, and for most employers it flows through an intermediary whose economics they have never actually seen.
That intermediary is the pharmacy benefit manager. And in 2026, for the first time in a decade, the rules governing what a PBM must disclose to a self-funded plan are being rewritten — which changes both the risk and the opportunity.
The transparency shift is now regulatory, not aspirational. In late January 2026, the Department of Labor proposed a transparency rule aimed specifically at self-insured group health plans, which cover roughly two-thirds of workers with employer coverage. The proposal would require covered service providers to disclose compensation at least thirty days before a contract or renewal, report spread pricing and manufacturer rebates on both an aggregate and a per-drug basis, and give plan fiduciaries defined audit rights. Days later, the Federal Trade Commission reached a settlement with one of the largest PBMs requiring it to unlink its compensation from drug list prices. These developments sit on top of the ERISA fiduciary framework the Consolidated Appropriations Act established — the same framework now producing fiduciary-breach litigation against plan sponsors over pharmacy costs. The message to employers is consistent: the plan sponsor, not the PBM, is the fiduciary, and we did not know what the PBM kept is no longer a defensible answer.
Why this lands in the captive conversation. Transparency creates leverage, but leverage only matters if the employer has a structure to use it. This is where the group-health captive earns its place. More than forty percent of employers are now using or considering captives to finance benefits, and the recent growth is concentrated among mid-market employers — often those with fewer than five hundred employees — using group captives rather than single-parent structures. Inside that structure, the employer can carve pharmacy out of the bundled medical arrangement, contract directly for transparent pass-through pricing, and route the specialty and high-cost drug exposure through the captive's retained layer with stop-loss above it. Advisers who run captive pharmacy carve-outs report net pharmacy cost reductions in the range of fifteen to thirty percent — not from denying care, but from removing spread pricing, capturing rebates the plan is entitled to, and managing utilization deliberately.
The specialty and GLP-1 exposure is exactly what a captive is built to absorb. The volatility employers fear from pharmacy is severity volatility — the specialty claimant, the gene therapy, the GLP-1 population that grows year over year. A captive does not make those costs disappear, but it changes who controls them. Retained in a disciplined captive layer with reinsurance above it, the specialty exposure is funded on the employer's own terms, the surplus in a good year stays on the employer's balance sheet, and the utilization-management decisions are made by a fiduciary who can see the whole picture rather than a vendor compensated on volume. The transparency rules make that picture legible for the first time; the captive gives the employer somewhere to act on it.
None of this is a reason to abandon a PBM or to chase the lowest headline rate. It is a reason to treat pharmacy as a governed risk rather than a delegated one. The employer that reads its PBM contract against the new disclosure standard, carves the exposure into a structure it controls, and documents the prudent process behind those decisions is managing both the cost and the fiduciary duty at the same time. The employer that renews the bundled arrangement unread is doing neither.
PFTN's 4-Step Strategic Process brings that discipline to the pharmacy line. Strategic Discovery surfaces the true pharmacy spend, the specialty and GLP-1 trajectory, and the terms buried in the current PBM contract. Risk Assessment tests those terms against the 2026 transparency standard and models what a carve-out and a captive layer would actually retain. Solution Design structures the pass-through contract, the captive retention, and the stop-loss above it with intention. Ongoing Optimization keeps the arrangement current as the rules, the rebates, and the drug pipeline change.
Pharmacy is where the next several years of health-plan cost will be won or lost. The employers who own that risk — transparently, deliberately, inside a structure they control — will be the ones still setting their own terms when everyone else is absorbing the trend.
Sources: Ropes & Gray — The Year of PBM Reform: Proposed Transparency Rule for Self-Insured Group Health Plans; Epstein Becker Green — 2026 Pharmacy Benefit Manager Reform: What Employers Need to Know; Business Group on Health — 2026 Employer Health Care Strategy Survey; Evernorth / Express Scripts (Fierce Healthcare) — Spending Growth on GLP-1s Outpacing Specialty Pharmacy; Spring Consulting / Captive.com — Captive Medical Stop-Loss Coverage: A Strategic Shield; WTW — Captive Insurance for Employee Benefits: Is It Right for Your Organization?; Aon — U.S. Employer Health Care Costs Expected to Rise 9.5 Percent in 2026; Peterson-KFF Health System Tracker — Employer Perspectives on Covering GLP-1 Agonists
— Ryan Mefford, President & Risk Advisor